Article Publish Status: FREE
Abstract Title:

Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells.

Abstract Source:

Cancer Lett. 2010 Apr 28 ;290(2):167-73. Epub 2009 Sep 30. PMID: 19796866

Abstract Author(s):

Elizabeth W LaPensee, Christopher R LaPensee, Sejal Fox, Sandy Schwemberger, Scott Afton, Nira Ben-Jonathan

Article Affiliation:

Elizabeth W LaPensee


Resistance to chemotherapy is a major problem facing breast cancer patients. Cisplatin, a highly effective DNA-damaging drug, has shown only little success in breast cancer treatment. We are reporting that low nanomolar doses of bisphenol A (BPA) or estradiol antagonize cisplatin cytotoxicity in breast cancer cells, with their effects not mediated via classical estrogen receptors. Although both compounds increase the expression of Bcl-2, a Bcl-2 inhibitor completely blocked the protective effects of BPA while only partially affecting those of estradiol. Blockade of BPA and E2 actions should sensitize ER-negative breast tumors to anti-cancer drugs and allow for the inclusion of cisplatin in treatment regimens.

Study Type : In Vitro Study
Additional Links
Additional Keywords : Drug: Cisplatin : CK(49) : AC(18)
Adverse Pharmacological Actions : Chemoresistance upregulation : CK(7) : AC(0)

Print Options

Key Research Topics

Sayer Ji
Founder of

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2021, Journal Articles copyright of original owners, MeSH copyright NLM.